Comparative Pharmacology
Head-to-head clinical analysis: NAPROXEN versus NEOPROFEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NAPROXEN versus NEOPROFEN.
NAPROXEN vs NEOPROFEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), thereby reducing the synthesis of prostaglandins involved in inflammation, pain, and fever.
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis and thereby decreasing inflammation, pain, and fever.
250-500 mg orally twice daily; maximum 1.5 g/day. For extended-release: 750-1000 mg orally once daily.
IV: 10 mg/kg over 15 minutes, followed by 5 mg/kg at 24, 48, and 72 hours after the first dose.
None Documented
None Documented
Terminal elimination half-life 12-17 hours (mean 14 hours); permits twice-daily dosing. Half-life prolonged in elderly and hepatic impairment.
Clinical Note
moderateNaproxen + Gatifloxacin
"Naproxen may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateNaproxen + Rosoxacin
"Naproxen may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateNaproxen + Levofloxacin
"Naproxen may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderateNaproxen + Trovafloxacin
"Naproxen may increase the neuroexcitatory activities of Trovafloxacin."
Terminal elimination half-life is approximately 2.5 to 4 hours in adults. In preterm neonates (target population for Neoprofen), half-life is prolonged due to immature renal function: mean 30.5 hours (range 20–50 hours) after first dose, decreasing to ~15 hours after third dose. Clinical relevance: requires careful dosing intervals in neonates to avoid accumulation.
Primarily renal (95% as unchanged naproxen and 6-O-desmethylnaproxen); <5% fecal via biliary excretion.
Ibuprofen is primarily excreted renally as metabolites (approximately 90% of the dose), with less than 1% excreted unchanged. A small fraction (≤10%) is eliminated via bile/feces. For Neoprofen (ibuprofen lysine specifically used for patent ductus arteriosus), renal excretion accounts for >90% of elimination, predominantly as glucuronide conjugates and hydroxylated metabolites.
Category D/X
Category C
NSAID
NSAID